Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development
8 years ago
R&D
After decades in the big leagues, Martin Mackay is going small — and he's delighted
8 years ago
People
Financing
Celldex brings out the ax in wake of breast cancer drug disaster, chopping a quarter of its staff
8 years ago
R&D
Pharma
'Site-less' trials in mind, Novartis launches an app for ophthalmology research
8 years ago
Pharma
Can Takeda actually close its $65B deal to buy Shire? Maybe, but analysts aren't sure they should
8 years ago
Deals
Pharma
Done deal? Takeda reaches a ‘breakthrough’ in Shire merger talks as deal announcement looms — Reuters
8 years ago
Deals
Arrested and charged with fraud, PixarBio CEO Frank Reynolds could face up to 20 years in prison
8 years ago
People
SCOTUS to biopharma: Inter partes reviews are here to stay, deal with it
8 years ago
Pharma
Sofinnova leads $32.4 million round for Italy's EryDel; Celgene expands collaboration with Zymeworks
8 years ago
News Briefing
Biotech stars Schleifer and Yancopoulos share $52M in 2017 compensation, even though Regeneron's share price swooned
8 years ago
People
Shire says Takeda has come up with a new buyout offer as reports spotlight a looming handshake deal
8 years ago
Deals
Protein degradation 2.0? Third Rock sinks $56M into Cedilla's unusual approach
8 years ago
Financing
Startups
Nextech leads a $56M round for the Revolution's move into the clinic
8 years ago
Financing
AstraZeneca’s Imfinzi/tremelimumab combo fizzles again on lung cancer
8 years ago
R&D
Longtime Sanofi R&D chief Elias Zerhouni is on his way out, handing the research reins to Roche vet John Reed
8 years ago
People
R&D
FDA orders a partial hold on Epizyme’s lead cancer drug tazemetostat following T-cell lymphoma case
8 years ago
R&D
FDA panel offers a wavering thumbs up for Eli Lilly's 2 mg baricitinib, thumbs down on 4 mg
8 years ago
Pharma
Bankrupt and weary, diet pill maker Orexigen to sell for $75M to Nalpropion
8 years ago
Deals
R&D
The under-40s: How does the next generation of biopharma executives view the future?
8 years ago
People
Special
Sanofi loses its German CSO and diabetes chief to Grünenthal; Roche touts longterm advantages of Ocrevus in treating ...
8 years ago
News Briefing
EMA committee recommends Alnylam's early-stage ATTR amyloidosis drug for orphan status
8 years ago
Pharma
Pfizer hits stumbling block on Herceptin rival, but wins 'breakthrough' status on MenB vaccine
8 years ago
R&D
Pharma
Sage files for an approval for its ‘breakthrough’ therapy for postpartum depression
8 years ago
Pharma
Penny stock biotech Synthetic Biologics sees its 'breakthrough' status pulled as FDA ponders safety issues
8 years ago
Pharma
First page
Previous page
1044
1045
1046
1047
1048
1049
1050
Next page
Last page